Xalkori is expected to exceed KRW 10 billion in the amount of claims for the first time of the year
The Pfizer Korea’s lung cancer treatment ‘Xalkori Cap(crizotinib)’ has been launched with the insurance benefit on the last 1st. It is expected that it will exceed KRW 14.5 billion in the first year’s claim amount due to its high cost.
According to the Ministry of Health and Welfare on the 5th, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
